Caraco Recalls Venlafaxine Hydrochloride Extended-Release Tablets for Dissolution Failures
Caraco Pharmaceutical Laboratories is recalling 160,105 bottles of Venlafaxine Hydrochloride Extended-Release Tablets, 150 mg, because stability results showed the product did not meet drug release dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses or injuries, fitting the criteria for a moderate severity score related to potential therapeutic failure without immediate harm.
Plain-English summary
Caraco Pharmaceutical Laboratories, Ltd. is recalling 160,105 bottles of Venlafaxine Hydrochloride Extended-Release Tablets, 150 mg. The affected products are packaged in 30-count and 90-count bottles and were distributed nationwide and in Puerto Rico. The recall was initiated because stability results indicated that the product did not meet the required drug release dissolution specifications.
The recall covers specific lot numbers with expiration dates ranging from April 2014 to October 2014. The products were manufactured by Sun Pharmaceutical Ind. Ltd. in Gujarat, India, and distributed by Caraco Pharmaceutical Laboratories, Ltd. in Detroit, Michigan.
Consumers who have these specific products should stop using them and contact their healthcare provider or pharmacist for guidance on alternative treatment options. The recalled items should be returned to the pharmacy or disposed of according to local regulations.
The recalled product
- Product
- Venlafaxine Hydrochloride Extended-Release Tablets, 150 mg, packaged in a) 30-count bottles (NDC 41616-758-83, UPC 3 41616 75883 2); and b) 90-count bottles (NDC 41616-758-81, UPC 3 41616 75881 8), Rx only, Distributed by: Caraco Pharmaceutical Laboratories, Ltd., 1150 Elijah McC
- Manufacturer
- Caraco Pharmaceutical Laboratories, Ltd.
- Category
- Drug — Antidepressant
- Hazard
- Affected units
- 160,105
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (17)
- Lot #: a) JKL3354A
- Exp 04/14
- JKL5444A
- Exp 08/14
- JKL5457B
- JKL5445A
- Exp 09/14
- JKL5840A
- Exp 10/14
- JKL6588A
- Exp 11/14
- b) JKL3354B
- JKL5444B
- JKL5457C
- JKL5445B
- JKL5840B
- Exp 10/14.
Distribution
Part of a larger recall action
This product is one of 2 recalled by Caraco Pharmaceutical Laboratories, Ltd. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Caraco Pharmaceutical Laboratories, Ltd.
See all →- ModerateCaraco Recalls Cephalexin Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2014-08-13
- ModerateCaraco Recalls Cephalexin Capsules Due to Manufacturing Practice Deviations
FDA (Drugs) · 2014-08-13
- ModerateCaraco Recalls Venlafaxine Hydrochloride Extended-Release Tablets for Dissolution Failures
FDA (Drugs) · 2014-07-09
- SevereCaraco Recalls Gemcitabine Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-07-02
- ModerateCaraco Recalls Children's Cetirizine Tablets Due to Impurity Failures
FDA (Drugs) · 2014-05-07
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17